ArticleScientific reports2025
Irisin activates the AMPK-Beclin1 signaling pathway to regulate pulmonary autophagy induced by CSE + LPS.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Irisin maintains ER homeostasis and activates AMPK via integrin αVβ5 to attenuate CSE + LPS-induced emphysema and inflammation.Respiratory research · 2026Article
- Irisin, BMI, and SII as Predictors of Frequent Acute Exacerbations in COPD: Development of a Predictive Nomogram.International journal of chronic obstructive pulmonary disease · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Smoking and infection are the most common risk factors for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Irisin is a hormone-like substance that helps reduce oxidative stress and inflammation in lung diseases. This study aims to explore the potential regulatory mechanism of irisin in AECOPD induced by CSE combined with LPS. Autophagy-deficient models were established in mice and MH-S cells. Pathological changes in mouse lung tissues were assessed using HE staining, while Irisin expression was detected via immunofluorescence. Levels of IL-1β, IL-6, and TNF-α in mouse BALF and MH-S cell supernatants were measured by ELISA. Autophagic flux in MH-S cells was monitored using the Ad-mCherry-GFP-LC3B dual-fluorescence system and transmission electron microscopy. Western blotting was performed to analyze autophagy-related proteins in mice and MH-S cells, elucidating the molecular mechanism of Irisin's protective effects. Irisin can reduce the accumulation of the autophagy marker protein P62 and promote the conversion of LC3-I to LC3-II through the AMPK-Beclin1 pathway, increase autophagosome-lysosome formation, effectively restore damaged autophagic flux, and lower the levels of pro-inflammatory factors IL-1β, IL-6, and TNF-α elevated by CSE + LPS. Irisin activates protective autophagy through the AMPK-Beclin1 pathway, restores the autophagy imbalance induced by CSE + LPS in the lungs, reduces lung inflammation levels, and provides a new therapeutic target for the treatment of AECOPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.